Pseudoxanthoma Elasticum Clinical Trial
Official title:
Genetic Analysis of Patients With Pseudoxanthoma Elasticum (PXE)
Verified date | May 14, 2013 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will characterize the gene mutations responsible for pseudoxanthoma elasticum
(PXE) and correlate them with disease manifestations in males and females. PXE is an
inherited disorder that affects the connective tissue in some parts of the body. Calcium and
other minerals are deposited in the connective tissue, causing changes in the skin, eyes,
cardiovascular system and gastrointestinal system. Some effects of PXE can cause serious
medical problems, while others have less impact. Symptoms often appear earlier and are more
severe in females than in males, but there is no way to predict how the disorder will
progress in any given individual.
Candidates for this study are recruited through PXE International, an organization that
provides patient support and supports research on the disease. The organization collects
biological samples and medical information on patients and family members to help further
research on the disease. Families that have samples from the patient, both parents, and at
least one sibling may be eligible for this study. Grandparents and extended family members
may be included in certain instances.
Participants provide a blood sample, a sample of cells scraped from the inside of the cheek
(buccal cells) and a medical history. The samples are analyzed for gene variants and the
findings are correlated with disease signs and symptoms.
...
Status | Completed |
Enrollment | 188 |
Est. completion date | May 14, 2013 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility |
- INCLUSION/EXCLUSION CRITERIA: A representative set of collected families will be studied. No subjects within these families will be excluded. Families will be selected that have samples from both parents and at least one sibling in addition to the proband. The siblings will include both affected and unaffected. If grandparents are available they will also be typed to help in phase determination. Extended relatives will only be selected in multiple generation families. |
Country | Name | City | State |
---|---|---|---|
United States | National Cancer Institute (NCI), 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Bodzioch M, Orsó E, Klucken J, Langmann T, Böttcher A, Diederich W, Drobnik W, Barlage S, Büchler C, Porsch-Ozcürümez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet. 1999 Aug;22(4):347-51. — View Citation
Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001 Jul;11(7):1156-66. Review. — View Citation
Hagedorn C. Influences of soil acidity on Streptomyces populations inhabiting forest soils. Appl Environ Microbiol. 1976 Sep;32(3):368-75. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02537054 -
Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)
|
Phase 2 | |
Completed |
NCT05569252 -
A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
|
Phase 2 | |
Recruiting |
NCT05662085 -
Progression Rate of Pseudoxanthoma Elasticum-associated Choroidal and Retinal Degeneration
|
||
Completed |
NCT03070860 -
What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum
|
N/A | |
Completed |
NCT01446393 -
Functional and Structural Characterization of Arteriopathy in Pseudoxanthoma Elasticum (PXE)
|
N/A | |
Completed |
NCT00470977 -
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT03758534 -
Natural History of GACI With or Without ARHR2 or PXE
|
||
Recruiting |
NCT05734196 -
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
|
Phase 1 | |
Not yet recruiting |
NCT06462547 -
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
|
Phase 2 | |
Recruiting |
NCT01446380 -
Phenotypic Expressions in a French Pseudoxanthoma-Elasticum Cohort
|
N/A | |
Recruiting |
NCT03813550 -
Intestinal Microbiota and Vitamin K Levels in PXE Patients (IMPROVE Study)
|
N/A | |
Not yet recruiting |
NCT03364504 -
Biological Collection of Kidney Cells
|
N/A | |
Active, not recruiting |
NCT02108392 -
Characterization of Pseudoxanthoma Elasticum
|
||
Recruiting |
NCT01731080 -
Arterial Wall Calcium Load in Pseudoxanthoma Elasticum
|
N/A | |
Completed |
NCT00555113 -
Evolution of Visual Impairment During Pseudoxanthoma Elasticum
|
N/A | |
Withdrawn |
NCT04441671 -
Oral Pyrophosphate Absorption in PXE Disease
|
Phase 2 | |
Recruiting |
NCT04868578 -
PPI Supplementation to Fight ECtopIc Calcification in PXE
|
N/A | |
Completed |
NCT05025722 -
Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings
|
||
Completed |
NCT01525875 -
Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)
|
Phase 2 | |
Completed |
NCT05246189 -
Employment of Patients With Pseudoxanthoma Elasticum
|